These results align with previous preclinical and clinical evidence (19), which has suggested that RING domain-deficient BRCA1 may promote resistance to PARP inhibitors and platinum therapy in breast cancer cell lines harboring a hemizygous BRCA1 185delAG mutation (25). The gene discussed is BRCA1; the disease is breast cancer.